PR Newswire06.13.19
Theromics Inc., a recently formed medical device company pioneering technologies for interventional oncology, has appointed Ron Murphy as CEO. Murphy succeeds former CEO Thomas Ryan.
Murphy has held previous CEO roles in medical device companies across multiple therapeutic platforms including orthopedics, cardiovascular and obstructive sleep apnea. Prior to that, he spent many years as an investment banker and more recently, director of Corporate Business Development at a major medical device manufacturer.
Murphy commented, "I am thrilled to be working with Dr. Dupuy and Dr. Park to commercialize this new technology to optimize thermal ablation and ultimately minimize the recurrence rate of these deadly cancers."
Additionally, Dr. Joseph Amaral has joined he Theromics Board of Directors.
Dr. Amaral most recently was vice president of Surgical Innovation (J&J Ethicon); vice president of Surgical Science/chief scientific officer (Ethicon Energy); and vice president of Science and Technology Medical Devices and Regenerative Medicine (J&J Corporation). Prior to that, he served as CEO and president of Rhode Island and Hasbro Children's Hospital in Providence R.I. Prior to that, he served as chairman, Department of Surgery Warren Alpert School of Medicine at Brown University, chief of Surgery of Rhode Island and Lifespan Hospitals and president of University Surgical Associates. Dr. Amaral co-developed the Harmonic Scalpel, the first ultrasonically activated surgical device.
Dr. Amaral stated, "The ability to enlarge and shape ablations and to reduce and eliminate the effects of local blood vessels on tumor recurrence is a leap forward in the minimally invasive management of patients with tumors. It is exciting to join the board of Theromics, the leaders of this new area of patient care."
Developed and licensed from Brown University, Theromics' lead product, HeatSYNC TA will provide clinicians another minimally invasive weapon to fight many of the deadliest types of cancer. HeatSYNC TA optimizes current thermal ablation technologies by making them more focused, patient-centric and cost efficient.
Murphy has held previous CEO roles in medical device companies across multiple therapeutic platforms including orthopedics, cardiovascular and obstructive sleep apnea. Prior to that, he spent many years as an investment banker and more recently, director of Corporate Business Development at a major medical device manufacturer.
Murphy commented, "I am thrilled to be working with Dr. Dupuy and Dr. Park to commercialize this new technology to optimize thermal ablation and ultimately minimize the recurrence rate of these deadly cancers."
Additionally, Dr. Joseph Amaral has joined he Theromics Board of Directors.
Dr. Amaral most recently was vice president of Surgical Innovation (J&J Ethicon); vice president of Surgical Science/chief scientific officer (Ethicon Energy); and vice president of Science and Technology Medical Devices and Regenerative Medicine (J&J Corporation). Prior to that, he served as CEO and president of Rhode Island and Hasbro Children's Hospital in Providence R.I. Prior to that, he served as chairman, Department of Surgery Warren Alpert School of Medicine at Brown University, chief of Surgery of Rhode Island and Lifespan Hospitals and president of University Surgical Associates. Dr. Amaral co-developed the Harmonic Scalpel, the first ultrasonically activated surgical device.
Dr. Amaral stated, "The ability to enlarge and shape ablations and to reduce and eliminate the effects of local blood vessels on tumor recurrence is a leap forward in the minimally invasive management of patients with tumors. It is exciting to join the board of Theromics, the leaders of this new area of patient care."
Developed and licensed from Brown University, Theromics' lead product, HeatSYNC TA will provide clinicians another minimally invasive weapon to fight many of the deadliest types of cancer. HeatSYNC TA optimizes current thermal ablation technologies by making them more focused, patient-centric and cost efficient.